On enabling early detection of cancer via DNA-based signatures in liquid biopsy.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e24262-e24262 ◽  
Author(s):  
Bahram Ghaffarzadeh Kermani
2019 ◽  
Vol 25 (1) ◽  
pp. 1-9
Author(s):  
Benjamin Mwesige ◽  
Seung-Gu Yeo ◽  
Byong Chul Yoo

Author(s):  
Sinong Jia ◽  
Li Xie ◽  
Lei Li ◽  
Ying Qian ◽  
Jie Wang ◽  
...  

2018 ◽  
Vol 8 (2) ◽  
pp. 1399-1407
Author(s):  
Sameer Chhetri Aryal ◽  
Gopi Aryal

Cancers of the uterine cervix, breast, lung and stomach are four of the most common cancers in Nepal. Lack of knowledge and awareness about cancer, its risk factors and negligence of the early warning signs play crucial role in raising the incidence of the cancer. Curative therapies are most successful when cancer is diagnosed and treated at an early stage.Organized cancer screening programmes provide screening to target population and use multidisciplinary delivery teams, coordinated clinical oversight committees, and regular review by a multidisciplinary evaluation board. For population-based screening programs, decision- making and governance structures, tasks and procedures need to be defined.In this paper, we review population-based cancer screening programmes of different countries and share recommendations and relevant evidence for screening and early detection of common cancers in Nepal. The evidence-based recommendations provided in this Review are intended to act as a guide for policy makers, clinicians, and public health practitioners who are developing and implementing strategies in cancer control.  We also discuss the role of liquid biopsy in early detection, diagnosis and monitoring of cancers using circulating biomarkers. Despite challenges, time has come to include cell free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), as a parameters for early detection of cancer in the days to come.


2014 ◽  
Vol 50 ◽  
pp. S238
Author(s):  
R.M. Trigg ◽  
S.M. Giblett ◽  
C.A. Pritchard ◽  
J.A. Shaw

2021 ◽  
Author(s):  
Shawn Baldacchino

Liquid biopsy solutions are available for niche clinical applications. The patient benefits of such solutions are evident: ease of sampling, acceptable and repeatable. To date a number of solutions have received regulatory approval with more comprehensive, multi-cancer companion diagnostic approaches receiving approval in late 2020. Given these breakthrough advances and the ongoing clinical studies in early detection of cancer, the liquid biopsy field is making strides in technology. While circulating tumour DNA (ctDNA) solutions are quickly penetrating the market, strides in circulating tumour cells (CTC) and extracellular vesicles (EV) technologies is unlocking their potential for liquid biopsy. ctDNA solutions are paving the way towards clinical translation into the distinct applications across the cancer continuum. This chapter presents a detailed review of current approved liquid biopsy tests and provides a summary of advanced-stage prospective technologies within the context of distinctive clinical applications.


2021 ◽  
Vol 22 (11) ◽  
pp. 5601
Author(s):  
Dhruvajyoti Roy ◽  
Andreas Pascher ◽  
Mazen A. Juratli ◽  
Judith C. Sporn

The early detection of cancer favors a greater chance of curative treatment and long-term survival. Exciting new technologies have been developed that can help to catch the disease early. Liquid biopsy is a promising non-invasive tool to detect cancer, even at an early stage, as well as to continuously monitor disease progression and treatment efficacy. Various methods have been implemented to isolate and purify bio-analytes in liquid biopsy specimens. Aptamers are short oligonucleotides consisting of either DNA or RNA that are capable of binding to target molecules with high specificity. Due to their unique properties, they are considered promising recognition ligands for the early detection of cancer by liquid biopsy. A variety of circulating targets have been isolated with high affinity and specificity by facile modification and affinity regulation of the aptamers. In this review, we discuss recent progress in aptamer-mediated liquid biopsy for cancer detection, its associated challenges, and its future potential for clinical applications.


Sign in / Sign up

Export Citation Format

Share Document